T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Protein & Cell
;
(12): 254-266, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-757332
ABSTRACT
T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCR-engineered T cells began more than two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis and eradication. The success of these trials provided the foundation for clinical trials, including recent clinical successes using TCR-engineered T cells to target New York esophageal squamous cell carcinoma (NY-ESO-1). These successes demonstrate the potential of this approach to treat cancer. In this review, we provide a perspective on the current and future applications of TCR-engineered T cells for the treatment of cancer. Our summary focuses on TCR activation and both pre-clinical and clinical applications of TCR-engineered T cells. We also discuss how to enhance the function of TCR-engineered T cells and prolong their longevity in the tumor microenvironment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Receptores de Antígenos de Linfocitos T
/
Linfocitos T
/
Alergia e Inmunología
/
Genética
/
Metabolismo
/
Antígenos de Neoplasias
/
Neoplasias
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Protein & Cell
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS